Evidence map›Paper›PMID 17414317›Full record

ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)2007

Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.

German G Gomez, Carol A Kruse

Open access · greenAbstract read
In one paragraph

Article in Journal of immunotherapy (Hagerstown, Md. : 1997), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role of IL-17 in Glioma Progression.Journal of spine & neurosurgery · 2013
    Article
  5. Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  6. Article
  7. Review
  8. Immunotherapeutic approaches for glioma.Critical reviews in immunology · 2009
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

German G GomezDepartment of Pathology, University of Colorado Health Sciences Center, Denver, CO, USA.
Carol A Kruse
Institute for Molecular Medicine · USUniversity of Colorado Health · US

Funding

Proapoptotic Nucleic Acid Agents for Brain Tumor TherapyR21NS056300 · NINDS · SIDNEY KIMMEL CANCER CENTER · PI KRUSE, CAROL A · 2006 to 2007
$533k
ImmunoResistant Brain Tumor ModelsR21NS046463 · NINDS · UNIVERSITY OF COLORADO DENVER · PI KRUSE, CAROL A · 2003 to 2004
$424k
Minority Predoctoral Fellowship ProgramF31CA094834 · NCI · UNIVERSITY OF COLORADO DENVER · PI GOMEZ, GERMAN G · 2001 to 2004
$96k
NCI NIH HHS F31 CA094834NCI NIH HHS F31 CA94834NINDS NIH HHS NS-046463NINDS NIH HHS NS-056300NINDS NIH HHS R21 NS046463NINDS NIH HHS R21 NS056300
6 · The paper itself

Abstract

Two immunoresistant (IR) glioma cell variants, 13-06-IR29 and 13-06-IR30, were cloned from 13-06-MG glioma cell populations after receiving continuous immunoselective pressure from multiple alloreactive cytotoxic T lymphocyte (aCTL) preparations. Reapplication of aCTL immunoselective pressure to the IR clones, displaying a partial regain in sensitivity to aCTL after removal of the selective pressure, restored the resistance. The IR variants exhibited cross-resistance to non-human leukocyte antigen (HLA)-restricted effector cells and gamma-irradiation, but not to carmustine. The IR clones were characterized for factors that might contribute to the immunoresistance. The aCTL adhesion to extracellular matrix extracts derived from either the IR clones or the parental cells was similar and not impaired. Furthermore, aCTL binding to parental cells and IR clones was equal. Down-regulation of the cell recognition molecules, class I HLA or intercellular adhesion molecule-1 (ICAM-1), that would inhibit their recognition by aCTL was not observed on the IR clones. The down-regulation of Fas by the IR clones correlated with their resistance to FasL-induced apoptosis. HLA-G or FasL that might provide an immunotolerant environment or provide a means of counterattack to aCTL, respectively, were not associated with the IR phenotype. The aCTL, coincubated with the IR clones and parental cells, displayed up-regulation of multiple secreted cytokines. A significant up-regulation of bioactive transforming growth factor (TGF)-beta was observed in the IR clones compared with the parental cells. These data suggest that increased secretion of bioactive TGF-beta may inhibit aCTL lysis of the IR clones. Disruption of the TGF-beta signaling pathway may circumvent the resistance.

Indexed as

Antineoplastic Agents, AlkylatingApoptosisBrain NeoplasmsCalciumCarmustineCell AdhesionCell Line, TumorCoculture TechniquesCytokinesExtracellular MatrixFas Ligand Proteinfas ReceptorGamma RaysGliomaHLA-A AntigensHumansAntineoplastic Agents, AlkylatingCalciumCarmustineCytokinesFas Ligand Proteinfas ReceptorHLA-A AntigensIntercellular Adhesion Molecule-1Transforming Growth Factor beta

Identifiers

PMID17414317
PMCPMC1894900
OpenAlexW2035414562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.